GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » YoY EPS Growth

Cambium Bio (ASX:CMB) YoY EPS Growth : 50.00% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Cambium Bio's YoY EPS Growth for the quarter that ended in Dec. 2023 was 50.00%.

Cambium Bio's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was A$-0.00.


Cambium Bio YoY EPS Growth Historical Data

The historical data trend for Cambium Bio's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio YoY EPS Growth Chart

Cambium Bio Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.67 85.71 275.00 -300.00 57.14

Cambium Bio Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -160.00 37.50 11.11 140.00 50.00

Cambium Bio YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Cambium Bio's YoY EPS Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY EPS Growth (A: Jun. 2023 )
=(Earnings per Share (Diluted) (A: Jun. 2023 )-Earnings per Share (Diluted) (A: Jun. 2022 ))/ | Earnings per Share (Diluted) (A: Jun. 2022 ) |
=(-0.006--0.014)/ | -0.014 |
=57.14 %

Cambium Bio's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EPS Growth (Q: Dec. 2023 )
=(Earnings per Share (Diluted) (Q: Dec. 2023 )-Earnings per Share (Diluted) (Q: Dec. 2022 )) / | Earnings per Share (Diluted) (Q: Dec. 2022 )) |
=(-0.004--0.008)/ | -0.008 |
=50.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cambium Bio YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Cambium Bio's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Cambium Bio (ASX:CMB) Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines